Arvinas (ARVN) Total Liabilities (2017 - 2026)
Arvinas' (ARVN) quarterly Total Liabilities came in at $260.7 million in Q1 2026, down 23.55% year-on-year from $341.0 million in Q1 2025, and down 8.2% quarter-over-quarter from $284.0 million in Q4 2025.
Arvinas (ARVN) Total Liabilities (2017 - 2026) Analysis & Trends
Arvinas' Total Liabilities history runs 10 years deep, the most recent figure standing at $260.7 million for Q1 2026.
- On a quarterly basis, Total Liabilities fell 23.55% year-over-year to $260.7 million in Q1 2026; TTM through Mar 2026 was $260.7 million, a 23.55% decrease from a year earlier, with the FY2025 full-year figure at $284.0 million, down 46.38% from the prior year.
- Total Liabilities retreated to $260.7 million in Q1 2026 per ARVN's latest filing, from $284.0 million in the prior quarter.
- Across five years, Total Liabilities topped out at $765.0 million in Q1 2022 and bottomed at $260.7 million in Q1 2026.
- The 5-year median for Total Liabilities is $602.9 million (2024), against an average of $547.5 million.
- Across the five-year window, Total Liabilities jumped 1105.64% in 2022 and plunged 55.84% in 2025, its largest moves.
- Year by year, Total Liabilities stood at $703.9 million in 2022, then dropped by 8.42% to $644.6 million in 2023, then dropped by 17.83% to $529.7 million in 2024, then slumped by 46.38% to $284.0 million in 2025, then fell by 8.2% to $260.7 million in 2026.
- Per Business Quant, the three latest ARVN Total Liabilities figures stand at $260.7 million (Q1 2026), $284.0 million (Q4 2025), and $279.9 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | 60.46 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | 177.22 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 19.51 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 3.79 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 7.12 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 9.45 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | 15.48 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 753.82 Mn |
| 10 | Arvinas | 512.64 Mn | -102.26 Mn | - | 260.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 260.70 Mn |
| Dec 31, 2025 | 284.00 Mn |
| Sep 30, 2025 | 279.90 Mn |
| Jun 30, 2025 | 300.00 Mn |
| Mar 31, 2025 | 341.00 Mn |
| Dec 31, 2024 | 529.70 Mn |
| Sep 30, 2024 | 581.10 Mn |
| Jun 30, 2024 | 679.40 Mn |
| Mar 31, 2024 | 602.90 Mn |
| Dec 31, 2023 | 644.60 Mn |
| Sep 30, 2023 | 601.10 Mn |
| Jun 30, 2023 | 619.90 Mn |
| Mar 31, 2023 | 664.80 Mn |
| Dec 31, 2022 | 703.90 Mn |
| Sep 30, 2022 | 713.30 Mn |
| Jun 30, 2022 | 736.40 Mn |
| Mar 31, 2022 | 765.00 Mn |
| Dec 31, 2021 | 799.90 Mn |
| Sep 30, 2021 | 787.13 Mn |
| Jun 30, 2021 | 61.08 Mn |